Kaneka Of Japan To Buy Majority Of Eurogentec For Biopharma Entry
This article was originally published in PharmAsia News
Japan's Kaneka, a contract manufacturer of pharmaceuticals, said it intends to buy a majority share of Belgium's Eurogentec, maker of biologics for biopharmaceuticals, for about $44 million
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.